Jan Mazag

Executive Director at Slovakia State Institute for Drug Control

Jan Mazag

Jan Mazag

Executive Director at Slovakia State Institute for Drug Control

Biography

Jan
Mazag
WORK EXPERIENCE
1984–1988
Research employer
Drug Research Institute, (Slovakia)
Testing for activities of medicines in pre-clinical research
1988–1991
Head of dpt for biological testing of medicines
State Institute for Drug Control, (Slovakia)
Testing for pyrogens, dermatological safety and hypotensive effects based on requirements
1991–2002
Senior manager
Schering s.r.o., (Slovakia)
Regulatory and marketing activities
2003–2006
Head of Section of medicines
Ministry of Health, (Slovakia)
Legislative activities on medicines, pricing and reimbursement
March 2006–Present
Executive director
State Institute for Drug Control, (Slovakia)
Managing director of medicine agency
EDUCATION AND TRAINING
1978–1983
Prom pharm
Pharmaceutical faculty, (Slovakia)
1984–1984
Dr. Pharm
Pharmaceutical faculty, (Slovakia)
ADDITIONAL INFORMATION
Expertise
- Pharmacology of pharmaceuticals
- Evaluation of benefit and ad- benefit of pharmaceuticals comparing to present status of therapy
- regulatory requirements
Publications
1. VOGLER, S., ZIMMERMANN, N., MAZAG, J.: Procuring medicines in hospitals: results of the
European PHIS survey. EJHP Practice. 2011;2011(2):21.
2. VOGLER, S., ZIMMERMANN, N., HABL, C., MAZAG, J. : Jan Which role do discounts and loss
leaders play in medicine procurement in Austrian hospitals? A primary survey of official and actual
medicine prices, MS : 1765627472823418, Cost Effectiveness and Resource Allocation.2013, 11:15.
3. VOGLER, S., HABL, C., LEOPOLD, Ch., MAZAG, J., MORAK, S., ZIMMERMANN, N.: Phis
Hospital Pharma Report, Pharmaceutical Health Information System, Commissioned by the European
Commission, Executive Agency for Health and Consumers (EAHC) and the Austrian Ministry of
Health (BMG), May 2010, ISBN No: 13 978-3-85159-145-3
12/1/15
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page
1
/
2
Curriculum Vitae
Jan Mazag
4. Pharmaceutical Sector Country Profile, SLOVAKIA, Pharmaceutical Sector Country Profile Project
2011-2013, Pharmaceutical Sector Country Profiles Data and Reports,
http://www.who.int/medicines/areas/coordination/coordination_assessment/en/index1.html
5. VOGLER, S., HABL, C., LEOPOLD, Ch., MAZAG, J., MORAK, S., ZIMMERMANN, N.: PHIS
Hospital Pharma Report. Vienna: Pharmaceutical Health Information System; Gesundheit Österreich
GmbH / Geschäftsbereich ÖBIG, 2010.
6. VOGLER, S., ZIMMERMANN, N., LEOPOLD Ch., HABL, C., MAZAG, J.: Discounts and Rebates
Granted for Medicines for Hospital Use in Five European Countries. In: The Open
Pharmacoeconomics & Health Economics Journal, 5: 1-10
7. VOGLER, S., ZIMMERMANN, N., HABL, C., MAZAG, J.: The role of discounts and loss leaders in
medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices. In:
Cost Effectiveness and Resource Allocation, 11: 15
8. VOGLER, S., ZIMMERMANN, N., MAZAG, J.: Procuring medicines in hospitals: results of the
European PHIS survey. In: European Journal of Hospital Pharmacy Practice, 17: 20-21
9. VOGLER, S., HABL, C., LEOPOLD, Ch., MORAK, S., MAZAG, J., ZIMMERMANN, N.: PHIS
Hospital Pharma Report . May; Pharmaceutical Health Information System; Commissioned by the
Executive Agency for Health and Consumers and the Austrian Federal Ministry of Health
10. MAZAG, J.: PHIS Hospital Pharma Report Slovakia 2009. April; Pharmaceutical Health
Information System; Commissioned by the European Commission, Executive Agency for Health and
Consumers and the Austrian Federal Ministry of Health
11. MAZAG, J., SEGEC, A.: PPRI Pharma Profile Slovakia 2007. June; Pharmaceutical Pricing and
Reimbursement Information; Commissioned by the European Commission, Directorate-General
Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth
Projects
- 2007 - responsible for Country specific information related to processes for drug policy in Slovakia,
prepared by OECD Health division
- 2006 - 2008 member of team responsible for Country specific information on pharmaceuticals and
processes related with pharmaceuticlas in EU Member states under leadership of Austrian Institution
for Health
- 2008 - present - Project coordinator for Pharmaceutical Health Information System funded by EU DG
Sanco and DG Enterprise for Hospital Pharma processes - mapping and description of processes of
drug policies in EU member states with special focus on in-patient sector
Memberships
- Slovak Association for Pharmacoeconomy since 2005
- Austrian Health Institute since 2005 - Partner for country report
- Member of Management Board of EMA since 2006
- Member of HTA (Health Technology Assessment) board in Slovakia since 2010
- Member of Slovak association of Pharmacists - clinical pharmacology
Other Relevant Information
- VOGLER, S., MAZAG, J., LEOPOLD, Ch., ZIMMERMANN, N.: Generics promotion – analyzing
differences between the hospital and out-patient sectors. March/April; Poster at the European
Association of Hospital Pharmacists (EAHP) Congress
- VOGLER, S., ZIMMERMANN, N., LEOPOLD, Ch., HABL, C., MAZAG, J.: Are hospital medicines
prices influenced by discounts and rebates?. November; Poster at the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) Congress
- VOGLER, S., HABL, C., LEOPOLD, Ch., MAZAG, J., ZIMMERMANN, N.: Prices of Medicines,
Including High-Cost Cancer Medicines, in a Hospital Setting Compared to Outpatient Use. November;
Poster at the International Conferences on Improving Use of Medicines (ICIUM) Conference
- VOGLER, S., ZIMMERMANN, N., LEOPOLD, Ch., HABL, C., MAZAG, J.: Are hospital medicines
prices influenced by discounts and rebates?. December ; Poster at the Drug Utilisation and Health
Policy Meeting organised by EuroDURG
- VOGLER, S., MAZAG, J., LEOPOLD, Ch., ZIMMERMANN, N.: PHIS Hospital Pharma. April; Poster
at the Geneva Health Forum

Overview
Career Highlights

Slovakia State Institute for Drug Control

RelSci Relationships

485

Number of Boards

1

Relationships
RelSci Relationships are individuals Jan Mazag likely has professional access to. A relationship does not necessarily indicate a personal connection.

Head of Working Parties Secretariat (Ad Interim) at The European Medicines Agency

Relationship likelihood: Strong

Head, Public Engagement Department at The European Medicines Agency

Relationship likelihood: Strong

Executive Director at The European Medicines Agency

Relationship likelihood: Strong

Head of Labelling Review & Standards Office at The European Medicines Agency

Relationship likelihood: Strong

President at The Federal Institute for Drugs & Medical Devices

Relationship likelihood: Strong

Member, Committee for Advanced Therapies at The European Medicines Agency

Relationship likelihood: Strong

Director, Post-Licensing at Malta Medicines Authority

Relationship likelihood: Strong

General Director at European Brain Research Institute(EBRI)

Relationship likelihood: Strong

Head-Department of Hematology, Oncology, Tumor Immunology & Palliative Care at Helios Klinikum Berlin-Buch

Relationship likelihood: Strong

Former Chief Executive Officer at Medicines & Healthcare Products Regulatory Agency

Relationship likelihood: Strong

Paths to Jan Mazag
Potential Connections via
Relationship Science
You
Jan Mazag
Executive Director at Slovakia State Institute for Drug Control
Memberships
Member
2005 - Current
Member, Clinical Pharmacology
Current
Career History
Head of Section of Medicines
2003 - 2006
Boards & Committees
Member, Management Board
2006 - Current

The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.

Other Affiliations

Jan Mazag is affiliated with Slovakia Ministry of Health

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jan Mazag. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jan Mazag's profile does not indicate a business or promotional relationship of any kind between RelSci and Jan Mazag.